• Home
  • Latest
  • Fortune 500
  • Finance
  • Tech
  • Leadership
  • Lifestyle
  • Rankings
  • Multimedia
Right Arrow Button IconLeft Arrow Button IconHome
Right Arrow Button IconValeant Pharmaceuticals

Valeant Pharmaceuticals

Page 4 of 4
J. Michael Pearson, chief executive officer, Valeant Pharmaceuticals International Inc., speaks during the Bloomberg Economic Series: Canada 2015 in Toronto, Ontario Thursday May 21/2015. (Photo by Kevin Van Paassen/Bloomberg)
HealthValeant under federal investigation for how it prices drugs
By Laura LorenzettiOctober 15, 2015
J. Michael Pearson, Chairman of the board and Chief Executive Officer of Valeant Pharmaceuticals International Inc., waits for the start of their annual general meeting in Laval, Quebec
HealthBiotech stocks dive as lawmakers take aim at Valeant for drug price hikes
By Laura LorenzettiSeptember 28, 2015
MPWValeant had the hots for ‘female Viagra,’ Sprout CEO says
By Jen WiecznerAugust 20, 2015
Flibanserin
HealthValeant snaps up ‘Female Viagra’ maker Sprout for $1 billion
By Geoffrey SmithAugust 20, 2015
A Teva Pharmaceutical Industries factory in Jerusalem, Israel.
FinanceThe real reasons for the pharma merger boom
By Jen WiecznerJuly 28, 2015
157934085
FinanceTeva in talks to buy Allergan’s generic drug business
By ReutersJuly 26, 2015
J. Michael Pearson, Chairman of the board and Chief Executive Officer of Valeant Pharmaceuticals International Inc., speaks during their annual general meeting in Laval, Quebec
FinanceEndo International makes competing bid for Salix Pharmaceuticals
By ReutersMarch 11, 2015
IL: Corporations In Illinois
FinanceFat Pharma: Pfizer-Hospira and the top 10 overpriced drug deals ever
By Jen WiecznerFebruary 6, 2015
J. Michael Pearson, Chairman of the board and Chief Executive Officer of Valeant Pharmaceuticals International Inc., waits for the start of their annual general meeting in Laval, Quebec
FinanceAfter Allergan loss, is Valeant dumpster diving?
By Jen WiecznerJanuary 31, 2015
Pershing Square's Bill Ackman and Valeant Pharmaceuticals International's Michael Pearson Interview
FinanceZoetis shares spike on reported Ackman stake purchase
By Tom Huddleston Jr.November 11, 2014
FinanceIs Valeant the wrong partner for Bill Ackman’s bid for Allergan?
By Sanjay SanghoeeOctober 30, 2014
Botox
FinanceSEC is reportedly probing the Valeant-Ackman bid for Botox-maker Allergan
By Tom Huddleston Jr.August 14, 2014
FinanceMorgan Stanley caught playing both sides of Allergan-Valeant fight
By Tom Huddleston Jr.June 16, 2014
Valeant Offers to Buy Allergan With Pershing's Support
FinanceValeant injects more cash into bid for Botox-maker Allergan
By Tom Huddleston Jr.May 30, 2014
FinanceValeant ready to beef up bid for maker of Botox
By Laura LorenzettiMay 13, 2014
1
  • 1
  • 2
  • 3
  • 4
4
Most Popular
Law
DOGE cancelled a $349,000 grant to replace a museum’s HVAC after ChatGPT flagged it as DEI, court documents showAn image of a popular article
By Fortune EditorsMarch 19, 2026
Economy
Social Security has 6 years left. The fix that sounds cruelest may be the smartestAn image of a popular article
By Fortune EditorsMarch 19, 2026
Economy
Gen Z’s straight‑A boom is quietly shrinking their paychecksAn image of a popular article
By Fortune EditorsMarch 19, 2026
Fortune Secondary Logo
Rankings
  • 100 Best Companies
  • Fortune 500
  • Global 500
  • Fortune 500 Europe
  • Most Powerful Women
  • Future 50
  • World’s Most Admired Companies
  • See All Rankings
Sections
  • Finance
  • Fortune Crypto
  • Features
  • Leadership
  • Health
  • Commentary
  • Success
  • Retail
  • Mpw
  • Tech
  • Lifestyle
  • CEO Initiative
  • Asia
  • Politics
  • Conferences
  • Europe
  • Newsletters
  • Personal Finance
  • Environment
  • Magazine
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms Of Use
  • Single Issues For Purchase
  • International Print
Commercial Services
  • Advertising
  • Fortune Brand Studio
  • Fortune Analytics
  • Fortune Conferences
  • Business Development
  • Group Subscriptions
About Us
  • About Us
  • Editorial Calendar
  • Press Center
  • Work At Fortune
  • Diversity And Inclusion
  • Terms And Conditions
  • Site Map
  • About Us
  • Editorial Calendar
  • Press Center
  • Work At Fortune
  • Diversity And Inclusion
  • Terms And Conditions
  • Site Map
  • Facebook icon
  • Twitter icon
  • LinkedIn icon
  • Instagram icon
  • Pinterest icon

© 2026 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
FORTUNE is a trademark of Fortune Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.